Clinical studies have shown that treatment with thymosin alpha 1 increases response to vaccination.
William B. Ershler
Advertisement
William B. Ershler is deputy clinical director, clinical research branch, intramural research program, National Institute of Aging, National Institutes of Health, Baltimore, MD, and director at the Institute for Advanced Studies in Geriatric Medicine, Gaithersburg, MD.
Articles by William B. Ershler
Advertisement
Latest Updated Articles
Influenza Vaccine Enhancement with Immunomodulating Peptide Thymosin Alpha 1Published: January 2nd 2010 | Updated:
Advertisement
Advertisement
Trending on BioPharm International
1
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
2
Industry Leaders Detail Transformational Strategies to Mainstream CAR-T Care
3
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
4
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
5
